# Corrections welcome, dosing questions declined

> Contact Peptide Precision Planner — editorial correspondence — How to reach the editorial mailbox behind Peptide Precision Planner, and what kinds of correspondence it can and cannot act on.

**CONTACT**

An editorial mailbox for citations, corrections and study notifications.

## Editorial correspondence

Peptide Precision Planner is an editorial project rather than an organisation. It has no clinic, no laboratory, no product and no telephone number. The address behind it is a mailbox rather than a premises.

The correspondence it can act on is specific. A citation that has been misread. A number transcribed wrongly. A study that has appeared since a page was written and that fills a cell the matrix currently marks empty. That last one is the most valuable message this site can receive. A design brief becomes obsolete the moment the study it specifies is published, and the page should say so.

Useful correction notes identify the page, quote the disputed sentence, and name the supporting publication. New-study notices should state which compound and which design row the paper occupies. The editorial desk checks the source before changing the digest.

**Editorial mailbox:** editors@peptideprecisionplanner.com

## What the mailbox cannot do

It cannot supply a quantity, an interval or a schedule for any compound, and the reason is on every page of the site: for three of these four there is no approved human indication and therefore no dosing standard in existence to pass along.

It cannot advise on any individual situation. Nothing here is medical advice, and no correspondence creates a clinical relationship of any kind. Questions of that sort belong with a licensed clinician who can examine the person asking.

It does not source, arrange or recommend material, and it holds no commercial relationship with any supplier or manufacturer of the compounds discussed.

---

Peptide Precision Planner is an independent literature digest that specifies the studies four research peptides still lack; the only thing planned on these pages is a trial, and a trial is not a treatment.